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Background. Peripherally inserted central catheters (PICC) are used for treat-
ing infections requiring prolonged intravenous antibiotic therapy (IVAT) in children. 
Given the lack of data on rural PICC use as well as the rural nature of our state, we 
studied the safety of home PICC use for treating infections in children living in rural 
settings.
Methods. We identified children <18  years admitted from January 1, 2005 to 
March 1, 2014 to the University of New Mexico Hospital (UNMH) through analysis 
of 43 different ICD-9 and CPT codes indicative of PICC placement, with analysis of 
the medical record to identify patients discharged on IVAT. All data were entered 
into REDCap and analyzed on Stata. We recorded demographic data, the antibiotic 
used, the duration/indication for the PICC, and the type/timing of complications. To 
classify rural vs. urban residence, we used the rural-urban continuum code (RUCC) 
from U.S. Census data, and the driving time in hours (h) to the nearest level 1,2 or 
3 trauma center and UNMH using MapQuest. All patients had either weekly home 
health or clinic visits, but none utilized an outpatient parenteral antimicrobial therapy 
(OPAT) clinic. Linear regression models assessed for differences between outcome and 
response variables.
Results. Of 866 subjects with a PICC, 221 were discharged on IVAT. 134 (60.6%) 
were boys and 87 (39.4%) were girls (mean age 9.8 years). The mean driving time to 
the nearest level 1, 2, or 3 trauma center was 0.6 hours (range 0.1–3.0 hours), while 
the mean driving time to UNMH was 1.3 hours (range, 0.1–5.0 hours). PICCs were 
utilized for a mean of 26.1  days at home. The most common antibiotics used were 
tobramycin (n = 41) and nafcillin (n = 40). Osteoarticular infections and cystic fibrosis 
exacerbations were the most common indications for PICC use (68.8%). 47 children 
(21.3%) experienced complications associated with their PICC at a mean of 24.7 days 
from insertion, most commonly occlusion (n = 13, 27.7%) or accidental removal (n = 
13, 27.7%). 40 PICC’s (18.1%) were removed prematurely due to a complication. No 
association was found between RUCC’s or driving times to UNMH or the nearest level 
1, 2 or 3 trauma center with any of these complications nor with complications overall 
(P = 0.11 to 0.96).
Conclusion. Our study demonstrates that home IVAT with a PICC is safe in chil-
dren in rural locales.
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Background. The opioid epidemic has swept across the U.S. at a staggering rate, 
with an estimated half million to one million persons injecting drugs annually. Rates of 
hospitalization for injection drug use (IDU)-related infection have risen precipitously, 
comprising an escalating proportion of infectious diseases provider volume in highly 
impacted regions.
Methods. In March 2017, the Emerging Infections Network surveyed their 
national network of infectious diseases (ID) physicians to evaluate perspectives relat-
ing to the care of persons who inject drugs (PWID), including the frequency of, and 
management strategies for, IDU-related infection, the availability of addiction services, 
and the evolving role of ID physicians in the management of addiction.
Results. Over half (53%; N = 672) of 1,276 members with an adult ID practice 
participated; 78% (n = 526) reported treating PWID. Of 526 respondents, 464 (88%) 
reported seeing ≥1 patient per month with an IDU-related infection; 228 (43%) 
reported ≥6 per month. In the past year, 79% of respondents reported the majority 
of IDU-related infections seen required ≥2 weeks of parenteral therapy and reported 
frequently encountering skin and soft-tissue infections (61%), bacteremia/fungemia 
(53%), and endocarditis (50%). Strategies most commonly employed for management 
of prolonged parenteral antibiotic therapy included: completion of entire course on 
inpatient unit (by 41%) and transfer to supervised facility for completion (35%). Only 
35% of respondents agree/strongly agree their health system offers comprehensive 
treatment of substance use disorders (N = 181). Though nearly half of respondents 
felt that ID providers should actively manage substance use disorders (46%; N = 241), 
only 3% reported being waivered to prescribe buprenorphine for treatment of opioid 
use disorder.
Conclusion. The majority of infectious diseases physicians frequently care for 
PWID with serious infections. There is significant diversity amongst providers with 
regards to the availability of comprehensive addiction services as well as perceptions 
regarding the role providers should play in the management of addiction. Guidelines 
for the management of serious infections and concurrent addiction in the midst of the 
escalating national opioid crisis should be considered.
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Background. Injection drug use (IDU) is a growing epidemic, and persons who 
inject drugs (PWID) are at high risk for infection. IDU is a barrier to outpatient par-
enteral antimicrobial therapy (OPAT) and provider experience and knowledge may 
lead to variation in patient care. Recognizing this problem, a multi-disciplinary team 
implemented a protocol for management of PWID requiring IV antibiotics. The main 
goals were to standardize the evaluation and risk assessment of PWID with infections 
and to provide substance abuse counseling and treatment in order to decrease length 
of stay (LOS).
Methods. A protocol was developed outlining the evaluation, diagnosis, risk-as-
sessment, treatment, maintenance, and follow up of PWID requiring prolonged IV 
antibiotics (Figure  1). Patients meeting inclusion criteria were identified and the 
multidisciplinary team assessed the patient. ID confirmed the diagnosis and outlined 
the treatment plan, and addiction medicine performed a 9-point risk assessment. 
Low-risk patients were discharged to complete OPAT. Medium risk and high-risk 
patients remained hospitalized and were offered group therapy, opioid replacement 
therapy if applicable, and were reassessed weekly for discharge. These patients were 
compared with previously identified PWID requiring antibiotics prior to the protocol 
implementation.
Results. 37 patients pre-protocol were compared with 34 patients following 
implementation. Demographics were similar except 56% of the post-implementation 
group were diagnosed with a concomitant psychiatric disorder vs. 27% in the pre-im-
plementation group (P = 0.01). There was no statistical difference between the num-
ber of patients who left AMA in either group (13.5 % pre; 23.5% post; p 0.28) or the 
